ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,427,191, issued on Sept. 30, was assigned to MicroVAX LLC (Warrenton, Va.).
"SARS-CoV-2 fusion protein vaccine/regimen" was invented by Albert B. Deisseroth (Potomac, Md.).
According to the abstract* released by the U.S. Patent & Trademark Office: "A SARS-CoV-2 immunotherapeutic targeted fusion protein regimen or vaccine in which the extracellular domain (ecd) of the CD40L immunostimulatory protein, is attached individually to mRNA encoding a Selected Fragment of the Spike Protein (SFSP), representing a different functional feature and a different domain or domain region, or both of the Spike Protein, to generate 7 distinct SFSP/ecdCD40L translation units, each translation unit bein...